These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Benefits and challenges of hormone replacement therapy. Borgelt L; Umland E J Am Pharm Assoc (Wash); 2000; 40(5 Suppl 1):S30-1. PubMed ID: 11029858 [TBL] [Abstract][Full Text] [Related]
24. Weighing the risks and benefits of hormone therapy. Toth S; Blanchard E; Herman L; Larson L; Léger MM; McNellis R; Quigley T; Van Dyke E JAAPA; 2003 Jun; 16(6):45-7. PubMed ID: 14968505 [No Abstract] [Full Text] [Related]
25. [Hormone replacement therapy and the risk of breast cancer]. Hackmon R; Piura B; Mazor M Harefuah; 2002 Mar; 141(3):283-6, 313. PubMed ID: 11944224 [TBL] [Abstract][Full Text] [Related]
26. [Menopause in women--hormonal replacement therapy]. Kulikowski M; Tomaszewska I Pol Tyg Lek; 1995 Nov; 50(44-47):5-9. PubMed ID: 8643429 [No Abstract] [Full Text] [Related]
27. Friedan and estrogen: 'most unfortunate that she is so misinformed'. Meisner LF; Schinitsky MR Geriatrics; 1994 Mar; 49(3):11. PubMed ID: 8125348 [No Abstract] [Full Text] [Related]
28. Hormone replacement therapy: benefits and risks for the general postmenopausal female population and for women with a history of previously treated breast cancer. Bluming AZ Semin Oncol; 1993 Dec; 20(6):662-74. PubMed ID: 8296203 [No Abstract] [Full Text] [Related]
29. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Birkhäuser MH; Panay N; Archer DF; Barlow D; Burger H; Gambacciani M; Goldstein S; Pinkerton JA; Sturdee DW Climacteric; 2008 Apr; 11(2):108-23. PubMed ID: 18365854 [No Abstract] [Full Text] [Related]
31. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases]. Higuchi T; Mizunuma H Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136 [TBL] [Abstract][Full Text] [Related]
32. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy? Shulman LP J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108 [No Abstract] [Full Text] [Related]
34. Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces. Lagro-Janssen T; Rosser WW; van Weel C Lancet; 2003 Aug; 362(9382):414-5. PubMed ID: 12927422 [No Abstract] [Full Text] [Related]
36. Summaries for patients. Postmenopausal hormone replacement therapy to prevent chronic conditions: recommendations from the U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Ann Intern Med; 2002 Nov; 137(10):I48. PubMed ID: 12435233 [No Abstract] [Full Text] [Related]
37. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions: recommendations and rationale. Berg AO; Am J Nurs; 2003 Jun; 103(6):83-91. PubMed ID: 12802162 [No Abstract] [Full Text] [Related]
38. Hold the hormones? The good and the bad about postmenopausal estrogen therapy. Nemecek S Sci Am; 1997 Sep; 277(3):38, 40. PubMed ID: 9304196 [No Abstract] [Full Text] [Related]
39. [New insights on the effects of hormone replacement therapy on the breast tissue and the orgnaism]. Kubista E Wien Klin Wochenschr; 2003; 115 Suppl 2():46-9. PubMed ID: 15518146 [TBL] [Abstract][Full Text] [Related]
40. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis]. Urano T Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]